Fingerprint
Dive into the research topics of 'Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically